secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-016793
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing
----------------------------------------------------------------

- Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.
- Net loss of $3.5M for Q1 2023 improved $0.2M vs Q1 2022 net loss of $3.7M, aided by $1.0M deferred tax benefit.
- G&A expenses rose 53.7% to $3.5M due to insurance, marketing, and PIPE failure payments.
- VAR 200 investigator-initiated trial expected Q4 2023; IND submission for IC 100 anticipated Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/0001493152-23-016793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer